Emicizumab in acquired haemophilia A: about two clinical cases and literature review

Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansenne, Amandine, Hermans, Cedric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404634/
https://www.ncbi.nlm.nih.gov/pubmed/34471508
http://dx.doi.org/10.1177/20406207211038193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404634/
https://www.ncbi.nlm.nih.gov/pubmed/34471508
http://dx.doi.org/10.1177/20406207211038193

Ejemplares similares